Accelerated Approval Price Trends Show Sponsors Can ‘Lose But Not Win’ From Confirmatory Trials
Executive Summary
Study drills down into the lack of economic incentives for conducting confirmatory studies to inform policies that could remedy to the situation.
You may also be interested in...
Medicare Part B And Accelerated Approvals: MedPAC Mulls Use Of CED Versus Payment Caps
Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.
‘Dangling’ Accelerated Approvals: US FDA Flags Concerns About ‘Marginal’ Response Rates
Failed confirmatory trials for PD-1/L-1 inhibitor indications raise questions about marginal response rates in single-arm trials used to support accelerated approval, Oncology Center of Excellence leaders say in NEJM article that explains why the agency is taking six of these indications to its Oncologic Drugs Advisory Committee.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.